The litigation, spearheaded by Hagens Berman, targets the period between May 13, 2025, and February 19, 2026. Investors allege that company leadership misled the market by projecting confidence in the trial’s three-year design, despite possessing internal information that such a duration was insufficient to demonstrate a statistically significant reduction in late-stage cancer diagnoses. The share price plummeted over 50% immediately following the disclosure.

Hagens Berman partner Reed Kathrein is now investigating whether management knowingly ignored the limitations of the trial’s timeline while maintaining a facade of optimism. The firm is currently soliciting input from investors who suffered substantial losses and is seeking whistleblowers with non-public information regarding the trial’s design flaws. The deadline for investors to serve as lead plaintiff is August 4, 2026.